

# Sophia Hober

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7470940/publications.pdf>

Version: 2024-02-01

80  
papers

18,460  
citations

218677

26  
h-index

85541

71  
g-index

92  
all docs

92  
docs citations

92  
times ranked

37687  
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. <i>Journal of Internal Medicine</i> , 2022, 291, 72-80.	6.0	47
2	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. <i>Leukemia</i> , 2022, 36, 476-481.	7.2	25
3	A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. <i>New Biotechnology</i> , 2022, 66, 46-52.	4.4	5
4	SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. <i>PLoS ONE</i> , 2022, 17, e0262169.	2.5	29
5	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	4.4	19
6	Design of an integrated continuous downstream process for acid-sensitive monoclonal antibodies based on a calcium-dependent Protein A ligand. <i>Journal of Chromatography A</i> , 2022, 1664, 462806.	3.7	11
7	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. <i>Vaccines</i> , 2022, 10, 359.	4.4	11
8	Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e595.	2.7	6
9	Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins. <i>Metabolic Engineering</i> , 2022, 72, 171-187.	7.0	13
10	Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. <i>Clinical and Translational Immunology</i> , 2022, 11, e1388.	3.8	20
11	Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies. <i>Biotechnology and Bioengineering</i> , 2022, 119, 2152-2166.	3.3	25
12	Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension. <i>Molecular Pharmaceutics</i> , 2021, 18, 328-337.	4.6	8
13	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. <i>Biomaterials</i> , 2021, 266, 120381.	11.4	11
14	Phase I Study of <sup>99m</sup> Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 493-499.	5.0	41
15	Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. <i>Clinical and Translational Immunology</i> , 2021, 10, e1312.	3.8	24
16	Highly selective Protein A resin allows for mild sodium chloride-mediated elution of antibodies. <i>Journal of Chromatography A</i> , 2021, 1637, 461843.	3.7	7
17	High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers. <i>Journal of Infectious Diseases</i> , 2021, 224, 14-20.	4.0	8
18	Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2015.	7.4	286

#	ARTICLE	IF	CITATIONS
19	False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 666114.	4.8	17
20	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. <i>Journal of Infectious Diseases</i> , 2021, 224, 407-414.	4.0	43
21	Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. <i>Scandinavian Journal of Public Health</i> , 2021, 49, 707-712.	2.3	10
22	Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. <i>EBioMedicine</i> , 2021, 70, 103523.	6.1	42
23	Affinity-Based Methods for Site-Specific Conjugation of Antibodies. <i>Bioconjugate Chemistry</i> , 2021, 32, 1515-1524.	3.6	22
24	Secretome screening reveals immunomodulating functions of IFN $\gamma$ -7, PAP and GDF-7 on regulatory T-cells. <i>Scientific Reports</i> , 2021, 11, 16767.	3.3	6
25	Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. <i>iScience</i> , 2021, 24, 103078.	4.1	36
26	An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. <i>PLoS ONE</i> , 2021, 16, e0258041.	2.5	10
27	Differences in risk for SARS-CoV-2 infection among healthcare workers. <i>Preventive Medicine Reports</i> , 2021, 24, 101518.	1.8	17
28	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. <i>Pharmaceutics</i> , 2021, 13, 1847.	4.5	4
29	Zbasic: A Purification Tag for Selective Ion-Exchange Recovery. <i>Methods in Molecular Biology</i> , 2021, 2178, 149-158.	0.9	0
30	An Orthogonal Fusion Tag for Efficient Protein Purification. <i>Methods in Molecular Biology</i> , 2021, 2178, 159-166.	0.9	2
31	ZCa: A Protein A-Derived Domain with Calcium-Dependent Affinity for Mild Antibody Purification. <i>Methods in Molecular Biology</i> , 2021, 2178, 245-249.	0.9	0
32	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. <i>EBioMedicine</i> , 2021, 74, 103705.	6.1	161
33	SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. <i>Nature Communications</i> , 2020, 11, 5064.	12.8	243
34	Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein. <i>Molecules</i> , 2020, 25, 4448.	3.8	5
35	Engineering of Protein A for improved purification of antibodies and Fc-fused proteins. , 2020, , 35-54.		1
36	Improvements of a high-throughput protein purification process using a calcium-dependent setup. <i>Protein Expression and Purification</i> , 2020, 175, 105698.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Secretome-Based Screening in Target Discovery. <i>SLAS Discovery</i> , 2020, 25, 535-551.	2.7	15
38	High throughput generation of a resource of the human secretome in mammalian cells. <i>New Biotechnology</i> , 2020, 58, 45-54.	4.4	16
39	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , 2020, 12, 391.	4.5	7
40	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. <i>International Journal of Oncology</i> , 2019, 55, 309-319.	3.3	10
41	Optimization of a calcium-dependent Protein A-derived domain for mild antibody purification. <i>MAbs</i> , 2019, 11, 1492-1501.	5.2	13
42	Selection of the optimal macrocyclic chelators for labeling with <sup>111</sup> In and <sup>68</sup> Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 140, 109-120.	4.3	21
43	The human secretome. <i>Science Signaling</i> , 2019, 12, .	3.6	259
44	Phenotypic Screen with the Human Secretome Identifies FGF16 as Inducing Proliferation of iPSC-Derived Cardiac Progenitor Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6037.	4.1	13
45	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 134, 37-48.	4.3	21
46	Bispecific applications of non-immunoglobulin scaffold binders. <i>Methods</i> , 2019, 154, 143-152.	3.8	19
47	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. <i>Journal of Nuclear Medicine</i> , 2018, 59, 93-99.	5.0	29
48	Protein Engineering Allows for Mild Affinity-based Elution of Therapeutic Antibodies. <i>Journal of Molecular Biology</i> , 2018, 430, 3427-3438.	4.2	24
49	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with <sup>111</sup> In and <sup>68</sup> Ga. <i>Molecular Pharmaceutics</i> , 2018, 15, 2674-2683.	4.6	15
50	A subcellular map of the human proteome. <i>Science</i> , 2017, 356, .	12.6	2,079
51	A pathology atlas of the human cancer transcriptome. <i>Science</i> , 2017, 357, .	12.6	2,570
52	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , 2017, 7, 14780.	3.3	17
53	Site-Specific Photolabeling of the IgG Fab Fragment Using a Small Protein G Derived Domain. <i>Bioconjugate Chemistry</i> , 2016, 27, 2095-2102.	3.6	18
54	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. <i>Bioconjugate Chemistry</i> , 2016, 27, 2678-2688.	3.6	13

#	ARTICLE	IF	CITATIONS
55	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. <i>Bioconjugate Chemistry</i> , 2016, 27, 716-726.	3.6	38
56	Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 187-195.	2.1	8
57	Antibodies as means for selective mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1021, 3-13.	2.3	9
58	In vivo biotinylation and incorporation of a photo-inducible unnatural amino acid to an antibody-binding domain improve site-specific labeling of antibodies. <i>Biotechnology Journal</i> , 2015, 10, 564-574.	3.5	20
59	Tissue-based map of the human proteome. <i>Science</i> , 2015, 347, 1260419.	12.6	10,802
60	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , 2015, 75, 4364-4371.	0.9	55
61	Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin. <i>PLoS ONE</i> , 2014, 9, e103094.	2.5	50
62	Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 3973-3985.	5.4	28
63	THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING. <i>Computational and Structural Biotechnology Journal</i> , 2013, 6, e201303009.	4.1	85
64	Editorial: Biotech reviews on plants, lignocellulose, sequencing, genome engineering and Aspergilli. <i>Biotechnology Journal</i> , 2012, 7, 1057-1057.	3.5	0
65	Purification Systems Based on Bacterial Surface Proteins. , 2012, , .		4
66	Covalent Immunoglobulin Labeling through a Photoactivable Synthetic Z Domain. <i>Bioconjugate Chemistry</i> , 2011, 22, 2395-2403.	3.6	44
67	Engineering Bispecificity into a Single Albumin-Binding Domain. <i>PLoS ONE</i> , 2011, 6, e25791.	2.5	37
68	Editorial: Biotech reviews " keeping up with current developments. <i>Biotechnology Journal</i> , 2011, 6, 1031-1031.	3.5	1
69	A small bispecific protein selected for orthogonal affinity purification. <i>Biotechnology Journal</i> , 2010, 5, 605-617.	3.5	30
70	Editorial: Global biotech challenges. <i>Biotechnology Journal</i> , 2010, 5, 1249-1249.	3.5	0
71	Characterization of heat-labile uracil-DNA glycosylase from <i>Psychrobacter</i> sp. HJ147 and its application to the polymerase chain reaction. <i>Biotechnology and Applied Biochemistry</i> , 2009, 52, 167.	3.1	9
72	High-throughput protein production " Lessons from scaling up from 10 to 288 recombinant proteins per week. <i>Biotechnology Journal</i> , 2009, 4, 51-57.	3.5	41

#	ARTICLE	IF	CITATIONS
73	Editorial: Biotech in the post genomic era. <i>Biotechnology Journal</i> , 2009, 4, 1631-1631.	3.5	0
74	Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. <i>Protein Science</i> , 2009, 11, 206-213.	7.6	49
75	Protein A chromatography for antibody purification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 40-47.	2.3	435
76	Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 55, 407-416.	2.6	93
77	Structure, Specificity, and Mode of Interaction for Bacterial Albumin-binding Modules. <i>Journal of Biological Chemistry</i> , 2002, 277, 8114-8120.	3.4	83
78	Protein engineering of an IgG-binding domain allows milder elution conditions during affinity chromatography. <i>Journal of Biotechnology</i> , 2000, 76, 233-243.	3.8	80
79	Kinetic characterization of the interaction of the Z-fragment of protein A with mouse-IgG3 in a volume in chemical space. , 1999, 37, 494-498.		12
80	Insulin-like growth factors I and II are unable to form and maintain their native disulfides under in vivo redox conditions. <i>FEBS Letters</i> , 1999, 443, 271-276.	2.8	24